6. Bibliography

[1] A. N. Giaquinto *et al.*, "Breast Cancer Statistics, 2022," *CA. Cancer J. Clin.*, vol. 72, no. 6, pp. 524–541, Nov. 2022, doi: 10.3322/CAAC.21754.

[2] H. Sung *et al.*, "Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries," *CA. Cancer J. Clin.*, vol. 71, no. 3, pp. 209–249, May 2021, doi: 10.3322/CAAC.21660.

[3] S. F. Bakhoum *et al.*, "Chromosomal instability drives metastasis through a cytosolic DNA response," *Nature*, vol. 553, no. 7689, pp. 467–472, Jan. 2018, doi: 10.1038/NATURE25432.

[4] F. R. Balkwill, M. Capasso, and T. Hagemann, "The tumor microenvironment at a glance," *J. Cell Sci.*, 2012, doi: 10.1242/jcs.116392.

[5] F. Garrido, "MHC/HLA class I loss in cancer cells," *Adv. Exp. Med. Biol.*, vol. 1151, pp. 15–78, 2019, doi: 10.1007/978-3-030-17864-2_2.

[6] Y. Jiang, Y. Li, and B. Zhu, "T-cell exhaustion in the tumor microenvironment," *Cell Death Dis.*, vol. 6, no. 6, Jun. 2015, doi: 10.1038/CDDIS.2015.162.

[7] I. Melero, A. Rouzaut, G. T. Motz, and G. Coukos, "T-cell and NK-cell infiltration into solid tumors: a key limiting factor for efficacious cancer immunotherapy," *Cancer Discov.*, vol. 4, no. 5, pp. 522–526, 2014, doi: 10.1158/2159-8290.CD-13-0985.

[8] G. Housman *et al.*, "Drug resistance in cancer: An overview," *Cancers (Basel).*, vol. 6, no. 3, pp. 1769–1792, Sep. 2014, doi: 10.3390/cancers6031769.

[9] B. Cacho-Díaz, D. R. García-Botello, T. Wegman-Ostrosky, G. Reyes-Soto, E. Ortiz-Sánchez, and L. A. Herrera-Montalvo, "Tumor microenvironment differences between primary tumor and brain metastases," *J. Transl. Med.*, vol. 18, no. 1, Jan. 2020, doi: 10.1186/S12967-019-02189-8.

[10] J. B. Jacob, M. K. Jacob, and P. Parajuli, "Review of immune checkpoint inhibitors in immuno-oncology," *Adv. Pharmacol.*, vol. 91, pp. 111–139, Jan. 2021, doi: 10.1016/BS.APHA.2021.01.002.

[11] P. Bonaventura *et al.*, "Cold tumors: A therapeutic challenge for immunotherapy,"

Front. Immunol., vol. 10, no. FEB, p. 168, 2019, doi: 10.3389/FIMMU.2019.00168/BIBTEX.

[12] X. He and C. Xu, "Immune checkpoint signaling and cancer immunotherapy," *Cell Res.*, vol. 30, no. 8, pp. 660–669, Aug. 2020, doi: 10.1038/S41422-020-0343-4.

[13] F. Schütz, S. Stefanovic, L. Mayer, A. Von Au, C. Domschke, and C. Sohn, "PD-1/PD-L1 Pathway in Breast Cancer," *Oncol. Res. Treat.*, vol. 40, no. 5, pp. 294–297, Apr. 2017, doi: 10.1159/000464353.

[14] Y. T. Liu and Z. J. Sun, "Turning cold tumors into hot tumors by improving T-cell infiltration," *Theranostics*, vol. 11, no. 11, pp. 5265–5286, Mar. 2021, doi: 10.7150/THNO.58390.

[15] L. Müller, P. Aigner, and D. Stoiber, "Type I Interferons and Natural Killer Cell Regulation in Cancer," *Front. Immunol.*, vol. 8, no. MAR, p. 304, Mar. 2017, doi: 10.3389/FIMMU.2017.00304.

[16] P. Rizza, F. Moretti, and F. Belardelli, "Recent advances on the immunomodulatory effects of IFN-α: Implications for cancer immunotherapy and autoimmunity," *Autoimmunity*, vol. 43, no. 3, pp. 204–209, May 2010, doi: 10.3109/08916930903510880.

[17] S. Kojiro *et al.*, "Antiproliferative effects of 5-fluorouracil and interferon-alpha in combination on a hepatocellular carcinoma cell line in vitro and in vivo.," *J. Gastroenterol. Hepatol.*, vol. 21, no. 1 Pt 1, pp. 129–37, Jan. 2006, doi: 10.1111/j.1440-1746.2005.04154.x.

[18] R. M. Welsh, K. Bahl, H. D. Marshall, and S. L. Urban, "Type 1 interferons and antiviral CD8 T-cell responses.," *Plos Pathog.*, vol. 8, no. 1, pp. e1002352–e1002352, Jan. 2012, doi: 10.1371/JOURNAL.PPAT.1002352.

[19] R. Yu, B. Zhu, and D. Chen, "Type I interferon-mediated tumor immunity and its role in immunotherapy," *Cell. Mol. Life Sci.*, vol. 79, no. 3, pp. 1–24, Mar. 2022, doi: 10.1007/S00018-022-04219-Z/TABLES/4.

[20] E. Padovan, R. M. Landmann, and G. De Libero, "How pattern recognition receptor triggering influences T cell responses: a new look into the system," *Trends*

Immunol., vol. 28, no. 7, pp. 308–314, Jul. 2007, doi: 10.1016/J.IT.2007.05.002.

[21] S. S. Li and C. H. Mody, "NKp46 Is an NK Cell Fungicidal Pattern Recognition Receptor," *Trends Microbiol.*, vol. 24, no. 12, pp. 929–931, Dec. 2016, doi: 10.1016/J.TIM.2016.10.002.

[22] M. Escamilla-Tilch *et al.*, "The interplay between pathogen-associated and danger-associated molecular patterns: An inflammatory code in cancer," *Immunol. Cell Biol.*, vol. 91, no. 10, pp. 601–610, Nov. 2013, doi: 10.1038/ICB.2013.58.

[23] L. He *et al.*, "DNA sensors, crucial receptors to resist pathogens, are deregulated in colorectal cancer and associated with initiation and progression of the disease," *J. Cancer*, vol. 11, no. 4, pp. 893–905, 2020, doi: 10.7150/JCA.34188.

[24] R. Yang, S. Yu, T. Xu, J. Zhang, and S. Wu, "Emerging role of RNA sensors in tumor microenvironment and immunotherapy," *J. Hematol. Oncol.*, vol. 15, no. 1, Dec. 2022, doi: 10.1186/S13045-022-01261-Z.

[25] T. D, S. R, S. AK, P. CD, and S. R, "TRIM13 regulates ER stress induced autophagy and clonogenic ability of the cells," *Biochim. Biophys. Acta*, vol. 1823, no. 2, pp. 316–326, Feb. 2012, doi: 10.1016/J.BBAMCR.2011.11.015.

[26] Y. Zhu, X. An, X. Zhang, Y. Qiao, T. Zheng, and X. Li, "STING: a master regulator in the cancer-immunity cycle," *Mol. Cancer 2019 181*, vol. 18, no. 1, pp. 1–15, Nov. 2019, doi: 10.1186/S12943-019-1087-Y.

[27] C. A. Janeway and R. Medzhitov, "Innate immune recognition," *Annu. Rev. Immunol.*, vol. 20, pp. 197–216, 2002, doi: 10.1146/ANNUREV.IMMUNOL.20.083001.084359.

[28] M. Jiang *et al.*, "CGAS-STING, an important pathway in cancer immunotherapy," *J. Hematol. Oncol.*, vol. 13, no. 1, pp. 1–11, Jun. 2020, doi: 10.1186/S13045-020-00916-Z/FIGURES/4.

[29] X. Zhang *et al.*, "Cyclic GMP-AMP Containing Mixed Phosphodiester Linkages Is An Endogenous High-Affinity Ligand for STING," *Mol. Cell*, vol. 51, no. 2, pp. 226–235, Jul. 2013, doi: 10.1016/J.MOLCEL.2013.05.022.

[30] P. J. Kranzusch, "cGAS and CD-NTase enzymes: structure, mechanism, and evolution," *Curr. Opin. Struct. Biol.*, vol. 59, p. 178, Dec. 2019, doi: 10.1016/J.SBI.2019.08.003.

[31] W. Zhou *et al.*, "Structure of the Human cGAS-DNA Complex Reveals Enhanced Control of Immune Surveillance The structure of the human cGAS-DNA complex reveals regulatory adaptations that balance enzymatic activity with DNA-length sensitivity, and additional features important for drug design," *Cell*, vol. 174, pp. 300-311.e11, 2018, doi: 10.1016/j.cell.2018.06.026.

[32] M. Du and Z. J. Chen, "DNA-induced liquid phase condensation of cGAS activates innate immune signaling," *Science (80-.).*, vol. 361, no. 6403, pp. 704–709, Aug. 2018, doi: 10.1126/SCIENCE.AAT1022/SUPPL_FILE/AAT1022S1.MP4.

[33] H. Ishikawa and G. N. Barber, "STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling," *Nature*, vol. 455, no. 7213, pp. 674–678, Oct. 2008, doi: 10.1038/nature07317.

[34] S. L. Ergun, D. Fernandez, T. M. Weiss, and L. Li, "STING Polymer Structure Reveals Mechanisms for Activation, Hyperactivation, and Inhibition," *Cell*, vol. 178, no. 2, pp. 290-301.e10, Jul. 2019, doi: 10.1016/J.CELL.2019.05.036.

[35] G. Shang, C. Zhang, Z. J. Chen, X. chen Bai, and X. Zhang, "Cryo-EM structures of STING reveal its mechanism of activation by cyclic GMP–AMP," *Nat. 2019 5677748*, vol. 567, no. 7748, pp. 389–393, Mar. 2019, doi: 10.1038/s41586-019-0998-5.

[36] A. Y. Shih, K. L. Damm-Ganamet, and T. Mirzadegan, "Dynamic Structural Differences between Human and Mouse STING Lead to Differing Sensitivity to DMXAA," *Biophys. J.*, vol. 114, no. 1, p. 32, Jan. 2018, doi: 10.1016/J.BPJ.2017.10.027.

[37] J. M. Ramanjulu *et al.*, "Design of amidobenzimidazole STING receptor agonists with systemic activity," *Nature*, vol. 564, no. 7736, pp. 439–443, Dec. 2018, doi: 10.1038/S41586-018-0705-Y.

[38] K. Mukai *et al.*, "Activation of STING requires palmitoylation at the Golgi," *Nat.*

Commun., vol. 7, Jun. 2016, doi: 10.1038/NCOMMS11932.

[39] K. P. Hopfner and V. Hornung, "Molecular mechanisms and cellular functions of cGAS–STING signalling," *Nat. Rev. Mol. Cell Biol. 2020 219*, vol. 21, no. 9, pp. 501–521, May 2020, doi: 10.1038/s41580-020-0244-x.

[40] A. Emam, X. Wu, S. Xu, L. Wang, S. Liu, and B. Wang, "Stalled replication fork protection limits cGAS-STING and P-body-dependent innate immune signalling," *Nat. Cell Biol.*, vol. 24, no. 7, pp. 1154–1164, Jul. 2022, doi: 10.1038/S41556-022-00950-8.

[41] H. Chen *et al.*, "cGAS suppresses genomic instability as a decelerator of replication forks," *Sci. Adv.*, vol. 6, no. 42, Oct. 2020, doi: 10.1126/SCIADV.ABB8941.

[42] H. Yang, H. Wang, U. Ren, Q. Chen, and Z. J. Chena, "CGAS is essential for cellular senescence," *Proc. Natl. Acad. Sci. U. S. A.*, vol. 114, no. 23, pp. E4612–E4620, Jun. 2017, doi: 10.1073/PNAS.1705499114/SUPPL_FILE/PNAS.1705499114.SM01.AVI.

[43] T. Li *et al.*, "Phosphorylation and Chromatin Tethering Prevent cGAS activation During Mitosis," *Science*, vol. 371, no. 6535, Mar. 2021, doi: 10.1126/SCIENCE.ABC5386.

[44] H. Liu *et al.*, "Nuclear cGAS suppresses DNA repair and promotes tumorigenesis," *Nature*, vol. 563, no. 7729, pp. 131–136, Nov. 2018, doi: 10.1038/S41586-018-0629-6.

[45] A. D. Jeyasekharan, "PARP inhibitors need an extra STING for therapeutic efficacy," *Sci. Transl. Med.*, vol. 11, no. 494, May 2019, doi: 10.1126/SCITRANSLMED.AAX9557.

[46] L. Ding *et al.*, "PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer," *Cell Rep.*, vol. 25, no. 11, p. 2972, Dec. 2018, doi: 10.1016/J.CELREP.2018.11.054.

[47] J. Ahn, T. Xia, H. Konno, K. Konno, P. Ruiz, and G. N. Barber, "Inflammation-driven carcinogenesis is mediated through STING," *Nat. Commun. 2014 51*, vol. 5, no. 1, pp. 1–9, Oct. 2014, doi: 10.1038/ncomms6166.

[48] S. Hu *et al.*, "cGAS restricts colon cancer development by protecting intestinal barrier integrity," *Proc. Natl. Acad. Sci. U. S. A.*, vol. 118, no. 23, Jun. 2021, doi: 10.1073/PNAS.2105747118/SUPPL_FILE/PNAS.2105747118.SAPP.PDF.

[49] A. Ablasser *et al.*, "Cell intrinsic immunity spreads to bystander cells via the intercellular transfer of cGAMP," *Nature*, vol. 503, no. 7477, p. 530, 2013, doi: 10.1038/NATURE12640.

[50] B. SF *et al.*, "Chromosomal instability drives metastasis through a cytosolic DNA response," *Nature*, vol. 553, no. 7689, pp. 467–472, Jan. 2018, doi: 10.1038/NATURE25432.

[51] K. J. Mackenzie *et al.*, "cGAS surveillance of micronuclei links genome instability to innate immunity," *Nature*, vol. 548, no. 7668, p. 461, Aug. 2017, doi: 10.1038/NATURE23449.

[52] L. Mohr, E. Toufektchan, P. von Morgen, K. Chu, A. Kapoor, and J. Maciejowski, "ER-directed TREX1 limits cGAS activation at micronuclei," *Mol. Cell*, vol. 81, no. 4, pp. 724-738.e9, Feb. 2021, doi: 10.1016/J.MOLCEL.2020.12.037.

[53] C. Hong *et al.*, "cGAS–STING drives the IL-6-dependent survival of chromosomally instable cancers," *Nat. 2022*, pp. 1–8, Jun. 2022, doi: 10.1038/s41586-022-04847-2.

[54] D. G *et al.*, "Non-canonical Activation of the DNA Sensing Adaptor STING by ATM and IFI16 Mediates NF-κB Signaling after Nuclear DNA Damage," *Mol. Cell*, vol. 71, no. 5, pp. 745-760.e5, Sep. 2018, doi: 10.1016/J.MOLCEL.2018.07.034.

[55] L. Yu and P. Liu, "Cytosolic DNA sensing by cGAS: regulation, function, and human diseases," *Signal Transduct. Target. Ther. 2021 61*, vol. 6, no. 1, pp. 1–15, Apr. 2021, doi: 10.1038/s41392-021-00554-y.

[56] R. B. Cary, S. R. Peterson, J. Wang, D. G. Bear, E. M. Bradbury, and D. J. Chen, "DNA looping by Ku and the DNA-dependent protein kinase," *Proc. Natl. Acad. Sci. U. S. A.*, vol. 94, no. 9, p. 4267, Apr. 1997, doi: 10.1073/PNAS.94.9.4267.

[57] K. Burleigh *et al.*, "Human DNA-PK activates a STING-independent DNA sensing

pathway," *Sci. Immunol.*, vol. 5, no. 43, Jan. 2020, doi: 10.1126/SCIIMMUNOL.ABA4219.

[58] L. Cheradame *et al.*, "STING Promotes Breast Cancer Cell Survival by an Inflammatory-Independent Nuclear Pathway Enhancing the DNA Damage Response," *bioRxiv*, p. 2020.07.11.196790, Jul. 2020, doi: 10.1101/2020.07.11.196790.

[59] S. Zou, Q. Tong, B. Liu, W. Huang, Y. Tian, and X. Fu, "Targeting STAT3 in Cancer Immunotherapy," *Mol. Cancer 2020 191*, vol. 19, no. 1, pp. 1–19, Sep. 2020, doi: 10.1186/S12943-020-01258-7.

[60] J. Ma, L. Qin, and X. Li, "Role of STAT3 signaling pathway in breast cancer," *Cell Commun. Signal. 2020 181*, vol. 18, no. 1, pp. 1–13, Feb. 2020, doi: 10.1186/S12964-020-0527-Z.

[61] H. Vasiyani *et al.*, "DNA damage induces STING mediated IL-6-STAT3 survival pathway in triple-negative breast cancer cells and decreased survival of breast cancer patients," *Apoptosis*, vol. 27, no. 11–12, 2022, doi: 10.1007/S10495-022-01763-8.

[62] A. Jahangiri, M. Dadmanesh, and K. Ghorban, "STAT3 inhibition reduced PD-L1 expression and enhanced antitumor immune responses," *J. Cell. Physiol.*, vol. 235, no. 12, pp. 9457–9463, Dec. 2020, doi: 10.1002/JCP.29750.

[63] X. Jiang *et al.*, "HJC0152, a novel STAT3 inhibitor with promising anti-tumor effect in gastric cancer," *Cancer Manag. Res.*, vol. 10, p. 6857, 2018, doi: 10.2147/CMAR.S188364.

[64] S. S. Al-Asmari, A. Rajapakse, T. R. Ullah, G. Pépin, L. V. Croft, and M. P. Gantier, "Pharmacological Targeting of STING-Dependent IL-6 Production in Cancer Cells," *Front. cell Dev. Biol.*, vol. 9, Jan. 2022, doi: 10.3389/FCELL.2021.709618.

[65] S. Luecke *et al.*, "cGAS is activated by DNA in a length-dependent manner," *EMBO Rep.*, vol. 18, no. 10, p. 1707, Oct. 2017, doi: 10.15252/EMBR.201744017.

[66] L. Andreeva *et al.*, "cGAS senses long and HMGB/TFAM-bound U-turn DNA by

forming protein-DNA ladders," *Nature*, vol. 549, no. 7672, pp. 394–398, Sep. 2017, doi: 10.1038/NATURE23890.

[67] N. Gehrke *et al.*, "Oxidative damage of DNA confers resistance to cytosolic nuclease TREX1 degradation and potentiates STING-dependent immune sensing," *Immunity*, vol. 39, no. 3, pp. 482–495, Sep. 2013, doi: 10.1016/J.IMMUNI.2013.08.004.

[68] W. Zhou, L. Mohr, J. Maciejowski, and P. J. Kranzusch, "cGAS phase separation inhibits TREX1-mediated DNA degradation and enhances cytosolic DNA sensing," *Mol. Cell*, vol. 81, no. 4, pp. 739-755.e7, Feb. 2021, doi: 10.1016/J.MOLCEL.2021.01.024.

[69] A. Ablasser, I. Hemmerling, J. L. Schmid-Burgk, R. Behrendt, A. Roers, and V. Hornung, "TREX1 Deficiency Triggers Cell-Autonomous Immunity in a cGAS-Dependent Manner," *J. Immunol.*, vol. 192, no. 12, pp. 5993–5997, Jun. 2014, doi: 10.4049/JIMMUNOL.1400737.

[70] L. Zhong, M. M. Hu, L. J. Bian, Y. Liu, Q. Chen, and H. B. Shu, "Phosphorylation of cGAS by CDK1 impairs self-DNA sensing in mitosis," *Cell Discov. 2020 61*, vol. 6, no. 1, pp. 1–12, Apr. 2020, doi: 10.1038/s41421-020-0162-2.

[71] G. J. Seo *et al.*, "Akt kinase-mediated checkpoint of cGAS DNA sensing pathway," *Cell Rep.*, vol. 13, no. 2, p. 440, Oct. 2015, doi: 10.1016/J.CELREP.2015.09.007.

[72] G. Xun, W. Hu, and B. Li, "PTEN loss promotes oncogenic function of STMN1 via PI3K/AKT pathway in lung cancer," *Sci. Rep.*, vol. 11, no. 1, Dec. 2021, doi: 10.1038/S41598-021-93815-3.

[73] T. Sun, Z. Liu, and Q. Yang, "The role of ubiquitination and deubiquitination in cancer metabolism," *Mol. Cancer*, vol. 19, no. 1, Oct. 2020, doi: 10.1186/S12943-020-01262-X.

[74] G. J. Seo, C. Kim, W. J. Shin, E. H. Sklan, H. Eoh, and J. U. Jung, "TRIM56-mediated monoubiquitination of cGAS for cytosolic DNA sensing," *Nat. Commun.*, vol. 9, no. 1, Dec. 2018, doi: 10.1038/S41467-018-02936-3.

[75] C. T. Hoffpauir *et al.*, "TRIM14 Is a Key Regulator of the Type I IFN Response

during Mycobacterium tuberculosis Infection," *J. Immunol.*, vol. 205, no. 1, pp. 153–167, Jul. 2020, doi: 10.4049/JIMMUNOL.1901511.

[76] Q. Wang *et al.*, "The E3 ubiquitin ligase RNF185 facilitates the cGAS-mediated innate immune response," *PLOS Pathog.*, vol. 13, no. 3, p. e1006264, Mar. 2017, doi: 10.1371/JOURNAL.PPAT.1006264.

[77] J. S. Lee, H. J. Choi, and S. H. Baek, "Sumoylation and Its Contribution to Cancer," *Adv. Exp. Med. Biol.*, vol. 963, pp. 283–298, Feb. 2017, doi: 10.1007/978-3-319-50044-7_17.

[78] Y. Cui *et al.*, "SENP7 Potentiates cGAS Activation by Relieving SUMO-Mediated Inhibition of Cytosolic DNA Sensing," *PLOS Pathog.*, vol. 13, no. 1, p. e1006156, Jan. 2017, doi: 10.1371/JOURNAL.PPAT.1006156.

[79] P. Xia *et al.*, "Glutamylation of the DNA sensor cGAS regulates its binding and synthase activity in antiviral immunity," *Nat. Immunol.*, vol. 17, no. 4, pp. 369–378, Apr. 2016, doi: 10.1038/NI.3356.

[80] J. Tao, X. Zhou, and Z. Jiang, "cGAS-cGAMP-STING: The three musketeers of cytosolic DNA sensing and signaling," *IUBMB Life*, vol. 68, no. 11, pp. 858–870, Nov. 2016, doi: 10.1002/IUB.1566.

[81] J. F. Foley, "Keeping cGAS under control," *Sci. Signal.*, vol. 9, no. 422, Apr. 2016, doi: 10.1126/SCISIGNAL.AAF8044.

[82] B. Song, T. M. Greco, K. K. Lum, C. Taber, and I. M. Cristea, "The DNA Sensor cGAS is Decorated by Acetylation and Phosphorylation Modifications in the Context of Immune Signaling," *Mol. Cell. Proteomics*, vol. 19, no. 7, p. 1193, Jul. 2020, doi: 10.1074/MCP.RA120.001981.

[83] J. Dai, Y.-J. Huang, Z.-G. Liu, X.-M. Zhang, and T. Li, "Acetylation Blocks cGAS Activity and Inhibits Self-DNA-Induced Autoimmunity Graphical Abstract Highlights d Acetylation suppresses cGAS activity d Aspirin directly acetylates cGAS d Aspirin inhibits cGAS-mediated interferon production d Aspirin alleviates DNA-induced autoimmunity in AGS mouse models and patient cells," *Cell*, vol. 176, pp. 1447-1460.e14, 2019, doi: 10.1016/j.cell.2019.01.016.

[84] Z. M. Song, H. Lin, X. M. Yi, W. Guo, M. M. Hu, and H. B. Shu, "KAT5 acetylates cGAS to promote innate immune response to DNA virus," *Proc. Natl. Acad. Sci. U. S. A.*, vol. 117, no. 35, pp. 21568–21575, Sep. 2020, doi: 10.1073/PNAS.1922330117/SUPPL_FILE/PNAS.1922330117.SAPP.PDF.

[85] S. Saha *et al.*, "Aspirin Suppresses the Acquisition of Chemoresistance in Breast Cancer by Disrupting an NFκB–IL6 Signaling Axis Responsible for the Generation of Cancer Stem Cells," *Cancer Res.*, vol. 76, no. 7, pp. 2000–2012, Apr. 2016, doi: 10.1158/0008-5472.CAN-15-1360.

[86] C. Wang, R. Zhang, X. Wei, M. Lv, and Z. Jiang, "Metalloimmunology: The metal ion-controlled immunity," *Adv. Immunol.*, vol. 145, pp. 187–241, Jan. 2020, doi: 10.1016/BS.AI.2019.11.007.

[87] P. Gao *et al.*, "Structure-function analysis of STING activation by c[G(2',5')pA(3',5')p] and targeting by antiviral DMXAA," *Cell*, vol. 154, no. 4, Aug. 2013, doi: 10.1016/J.CELL.2013.07.023.

[88] C. Wang, Y. Guan, X. Su, X. Huang, and Z. J. Correspondence, "Manganese Increases the Sensitivity of the cGAS-STING Pathway for Double-Stranded DNA and Is Required for the Host Defense against DNA Viruses In Brief," *Immunity*, vol. 48, pp. 675-687.e7, 2018, doi: 10.1016/j.immuni.2018.03.017.

[89] Z. Zhao, Z. Ma, B. Wang, Y. Guan, X. D. Su, and Z. Jiang, "Mn2+ Directly Activates cGAS and Structural Analysis Suggests Mn2+ Induces a Noncanonical Catalytic Synthesis of 2′3′-cGAMP," *Cell Rep.*, vol. 32, no. 7, p. 108053, Aug. 2020, doi: 10.1016/J.CELREP.2020.108053.

[90] M. Lv *et al.*, "Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy," *Cell Res.*, vol. 30, no. 11, pp. 966–979, Nov. 2020, doi: 10.1038/S41422-020-00395-4.

[91] X. Sun *et al.*, "Amplifying STING activation by cyclic dinucleotide–manganese particles for local and systemic cancer metalloimmunotherapy," *Nat. Nanotechnol. 2021 1611*, vol. 16, no. 11, pp. 1260–1270, Sep. 2021, doi: 10.1038/s41565-021-00962-9.

[92] X. Sun *et al.*, "Amplifying STING Activation by Cyclic Dinucleotide-Manganese Particles for Local and Systemic Cancer Metalloimmunotherapy," *Nat. Nanotechnol.*, vol. 16, no. 11, p. 1260, Nov. 2021, doi: 10.1038/S41565-021-00962-9.

[93] M. Gao *et al.*, "A Manganese Phosphate Nanocluster Activates the cGAS-STING Pathway for Enhanced Cancer Immunotherapy," *Adv. Ther.*, vol. 4, no. 8, p. 2100065, Aug. 2021, doi: 10.1002/ADTP.202100065.

[94] C. Wang, R. Zhang, X. Wei, M. Lv, and Z. Jiang, "Metalloimmunology: The metal ion-controlled immunity," *Adv. Immunol.*, vol. 145, pp. 187–241, Jan. 2020, doi: 10.1016/BS.AI.2019.11.007.

[95] F. Schwede, H. G. Genieser, and A. Rentsch, "The Chemistry of the Noncanonical Cyclic Dinucleotide 2'3'-cGAMP and Its Analogs," *Handb. Exp. Pharmacol.*, vol. 238, pp. 359–384, 2017, doi: 10.1007/164_2015_43.

[96] B. R. Morehouse *et al.*, "STING cyclic dinucleotide sensing originated in bacteria," *Nature*, vol. 586, no. 7829, pp. 429–433, Oct. 2020, doi: 10.1038/S41586-020-2719-5.

[97] A. Louie, V. Bhandula, and D. A. Portnoy, "Secretion of c-di-AMP by Listeria monocytogenes Leads to a STING-Dependent Antibacterial Response during Enterocolitis," *Infect. Immun.*, vol. 88, no. 12, Dec. 2020, doi: 10.1128/IAI.00407-20.

[98] N. Liu, X. Pang, H. Zhang, and P. Ji, "The cGAS-STING Pathway in Bacterial Infection and Bacterial Immunity," *Front. Immunol.*, vol. 12, Jan. 2021, doi: 10.3389/FIMMU.2021.814709.

[99] E. Van Dis *et al.*, "STING-Activating Adjuvants Elicit a Th17 Immune Response and Protect against Mycobacterium tuberculosis Infection," *Cell Rep.*, vol. 23, no. 5, pp. 1435–1447, May 2018, doi: 10.1016/J.CELREP.2018.04.003.

[100] Z. Z. Liu *et al.*, "STING Contributes to Host Defense Against Staphylococcus aureus Pneumonia Through Suppressing Necroptosis," *Front. Immunol.*, vol. 12, p. 2076, May 2021, doi: 10.3389/FIMMU.2021.636861/BIBTEX.

[101] S. Stockinger *et al.*, "Production of type I IFN sensitizes macrophages to cell death induced by Listeria monocytogenes," *J. Immunol.*, vol. 169, no. 11, pp. 6522–6529, Dec. 2002, doi: 10.4049/JIMMUNOL.169.11.6522.

[102] A. D. Tischler and A. Camilli, "Cyclic diguanylate (c-di-GMP) regulates Vibrio cholerae biofilm formation," *Mol. Microbiol.*, vol. 53, no. 3, p. 857, Aug. 2004, doi: 10.1111/J.1365-2958.2004.04155.X.

[103] X. Hu *et al.*, "Type I IFN expression is stimulated by cytosolic MtDNA released from pneumolysin-damaged mitochondria via the STING signaling pathway in macrophages," *FEBS J.*, vol. 286, no. 23, pp. 4754–4768, Dec. 2019, doi: 10.1111/FEBS.15001.

[104] J. S. Ruiz-Moreno *et al.*, "The cGAS/STING Pathway Detects Streptococcus pneumoniae but Appears Dispensable for Antipneumococcal Defense in Mice and Humans," *Infect. Immun.*, vol. 86, no. 3, Mar. 2018, doi: 10.1128/IAI.00849-17.

[105] S. Patel, H. R. Tucker, H. Gogoi, S. Mansouri, and L. Jin, "cGAS–STING and MyD88 Pathways Synergize in Ly6Chi Monocyte to Promote Streptococcus pneumoniae-Induced Late-Stage Lung IFNγ Production," *Front. Immunol.*, vol. 12, Aug. 2021, doi: 10.3389/fimmu.2021.699702.

[106] E. Movert, J. Lienard, C. Valfridsson, T. Nordström, B. Johansson-Lindbom, and F. Carlsson, "Streptococcal M protein promotes IL-10 production by cGAS-independent activation of the STING signaling pathway," *PLOS Pathog.*, vol. 14, no. 3, p. e1006969, Mar. 2018, doi: 10.1371/JOURNAL.PPAT.1006969.

[107] J. R. Barker *et al.*, "STING-dependent recognition of cyclic di-AMP mediates type I interferon responses during Chlamydia trachomatis infection," *MBio*, vol. 4, no. 3, 2013, doi: 10.1128/MBIO.00018-13.

[108] X. Z. Zhang, F. H. Li, and X. J. Wang, "Regulation of Tripartite Motif-Containing Proteins on Immune Response and Viral Evasion," *Front. Microbiol.*, vol. 12, p. 3680, Dec. 2021, doi: 10.3389/FMICB.2021.794882/BIBTEX.

[109] S. Hatakeyama, "TRIM Family Proteins: Roles in Autophagy, Immunity, and Carcinogenesis," *Trends Biochem. Sci.*, vol. 42, no. 4, pp. 297–311, Apr. 2017, doi:

10.1016/J.TIBS.2017.01.002.

[110] T. Tsuchida *et al.*, "The ubiquitin ligase TRIM56 regulates innate immune responses to intracellular double-stranded DNA," *Immunity*, vol. 33, no. 5, pp. 765–776, Nov. 2010, doi: 10.1016/J.IMMUNI.2010.10.013.

[111] J. Xing *et al.*, "TRIM29 promotes DNA virus infections by inhibiting innate immune response," *Nat. Commun. 2017 81*, vol. 8, no. 1, pp. 1–12, Oct. 2017, doi: 10.1038/s41467-017-00101-w.

[112] Q. Li *et al.*, "TRIM29 negatively controls antiviral immune response through targeting STING for degradation," *Cell Discov. 2018 41*, vol. 4, no. 1, pp. 1–13, Mar. 2018, doi: 10.1038/s41421-018-0010-9.

[113] Y. Wang *et al.*, "TRIM30α Is a Negative-Feedback Regulator of the Intracellular DNA and DNA Virus-Triggered Response by Targeting STING," *PLoS Pathog.*, vol. 11, no. 6, Jun. 2015, doi: 10.1371/JOURNAL.PPAT.1005012.

[114] C. Gerada and K. M. Ryan, "Autophagy, the innate immune response and cancer," *Mol. Oncol.*, vol. 14, no. 9, pp. 1913–1929, Sep. 2020, doi: 10.1002/1878-0261.12774.

[115] D. Liu *et al.*, "STING directly activates autophagy to tune the innate immune response," *Cell Death Differ.*, vol. 26, no. 9, pp. 1735–1749, Sep. 2019, doi: 10.1038/S41418-018-0251-Z.

[116] D. Liu *et al.*, "STING directly activates autophagy to tune the innate immune response," *Cell Death Differ.*, vol. 26, no. 9, pp. 1735–1749, Sep. 2019, doi: 10.1038/S41418-018-0251-Z.

[117] H. C. Yin, S. L. Shao, X. J. Jiang, P. Y. Xie, W. S. Sun, and T. F. Yu, "Interactions between Autophagy and DNA Viruses," *Viruses*, vol. 11, no. 9, Sep. 2019, doi: 10.3390/V11090776.

[118] X. Gui *et al.*, "Autophagy induction via STING trafficking is a primordial function of the cGAS pathway," *Nat. 2019 5677747*, vol. 567, no. 7747, pp. 262–266, Mar. 2019, doi: 10.1038/s41586-019-1006-9.

[119] T. Prabakaran *et al.*, "Attenuation of cGAS-STING signaling is mediated by a p62/SQSTM1-dependent autophagy pathway activated by TBK1," *EMBO J.*, vol. 37, no. 8, Apr. 2018, doi: 10.15252/EMBJ.201797858.

[120] S. J. Dixon *et al.*, "Ferroptosis: An iron-dependent form of nonapoptotic cell death," *Cell*, vol. 149, no. 5, pp. 1060–1072, May 2012, doi: 10.1016/J.CELL.2012.03.042.

[121] C. Li, Y. Zhang, J. Liu, R. Kang, D. J. Klionsky, and D. Tang, "Mitochondrial DNA stress triggers autophagy-dependent ferroptotic death," *Autophagy*, vol. 17, no. 4, p. 948, 2021, doi: 10.1080/15548627.2020.1739447.

[122] X. Gui *et al.*, "Autophagy induction via STING trafficking is a primordial function of the cGAS pathway," *Nature*, vol. 567, no. 7747, pp. 262–266, Mar. 2019, doi: 10.1038/S41586-019-1006-9.

[123] J. R. Teijaro, "Type I interferons in viral control and immune regulation," *Curr. Opin. Virol.*, vol. 16, pp. 31–40, Feb. 2016, doi: 10.1016/J.COVIRO.2016.01.001.

[124] H. Guo *et al.*, "NLRX1 Sequesters STING to Negatively Regulate the Interferon Response, Thereby Facilitating the Replication of HIV-1 and DNA Viruses," *Cell Host Microbe*, vol. 19, no. 4, pp. 515–528, Apr. 2016, doi: 10.1016/J.CHOM.2016.03.001.

[125] X. Luo *et al.*, "HPV16 drives cancer immune escape via NLRX1-mediated degradation of STING," *J. Clin. Invest.*, vol. 130, no. 4, pp. 1635–1652, Apr. 2020, doi: 10.1172/JCI129497.

[126] M. S. J. Mangan and E. Latz, "NLRC3 puts the brakes on STING," *Immunity*, vol. 40, no. 3, p. 305, Mar. 2014, doi: 10.1016/J.IMMUNI.2014.02.007.

[127] K. Singh *et al.*, "NLRX1 regulates TNF-α-induced mitochondria-lysosomal crosstalk to maintain the invasive and metastatic potential of breast cancer cells," *Biochim. Biophys. acta. Mol. basis Dis.*, vol. 1865, no. 6, pp. 1460–1476, Jun. 2019, doi: 10.1016/J.BBADIS.2019.02.018.

[128] J. A. Smith, "STING, the Endoplasmic Reticulum, and Mitochondria: Is Three a Crowd or a Conversation?," *Front. Immunol.*, vol. 11, Jan. 2021, doi: 10.3389/FIMMU.2020.611347.

[129] J. Bai and F. Liu, "cGAS–STING signaling and function in metabolism and kidney diseases," *J. Mol. Cell Biol.*, vol. 13, no. 10, pp. 728–738, Dec. 2021, doi: 10.1093/JMCB/MJAB066.

[130] Y. Huang *et al.*, "Brown adipose TRX2 deficiency activates mtDNA-NLRP3 to impair thermogenesis and protect against diet-induced insulin resistance," *J. Clin. Invest.*, vol. 132, no. 9, May 2022, doi: 10.1172/JCI148852.

[131] D. Olagnier *et al.*, "Nrf2 negatively regulates STING indicating a link between antiviral sensing and metabolic reprogramming," *Nat. Commun.*, vol. 9, no. 1, Dec. 2018, doi: 10.1038/S41467-018-05861-7.

[132] M. T. R. Gomes *et al.*, "STING regulates metabolic reprogramming in macrophages via HIF-1α during Brucella infection," *PLoS Pathog.*, vol. 17, no. 5, May 2021, doi: 10.1371/JOURNAL.PPAT.1009597.

[133] L. Tao *et al.*, "Reactive oxygen species oxidize STING and suppress interferon production," *Elife*, vol. 9, pp. 1–23, Sep. 2020, doi: 10.7554/ELIFE.57837.

[134] K. I. Onyedibe, M. Wang, and H. O. Sintim, "ENPP1, an Old Enzyme with New Functions, and Small Molecule Inhibitors—A STING in the Tale of ENPP1," *Molecules*, vol. 24, no. 22, Nov. 2019, doi: 10.3390/MOLECULES24224192.

[135] L. Li *et al.*, "Hydrolysis of 2′3′-cGAMP by ENPP1 and design of non-hydrolyzable analogs," *Nat. Chem. Biol.*, vol. 10, no. 12, p. 1043, Dec. 2014, doi: 10.1038/NCHEMBIO.1661.

[136] B. Allard, M. S. Longhi, S. C. Robson, and J. Stagg, "The ectonucleotidases CD39 and CD73: novel checkpoint inhibitor targets," *Immunol. Rev.*, vol. 276, no. 1, p. 121, Mar. 2017, doi: 10.1111/IMR.12528.

[137] A. Weston *et al.*, "Abstract 3077: Preclinical studies of SR-8314, a highly selective ENPP1 inhibitor and an activator of STING pathway," pp. 3077–3077, Jul. 2019, doi: 10.1158/1538-7445.AM2019-3077.

[138] M. Kumar and R. G. Lowery, "Development of a High-Throughput Assay to Identify Inhibitors of ENPP1," *SLAS Discov.*, vol. 26, no. 5, pp. 740–746, Jun. 2021, doi: 10.1177/2472555220982321.

[139] F. Meric-Bernstam *et al.*, "Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas," *Clin. Cancer Res.*, vol. 28, no. 4, pp. 677–688, Feb. 2022, doi: 10.1158/1078-0432.CCR-21-1963/674040/AM/PHASE-I-DOSE-ESCALATION-TRIAL-OF-MIW815-ADU-S100.

[140] A. H. Zaidi *et al.*, "Intratumoral immunotherapy with STING agonist, ADU-S100, induces CD8+ T-cell mediated anti-tumor immunity in an esophageal adenocarcinoma model," *Oncotarget*, vol. 12, no. 4, pp. 292–303, Feb. 2021, doi: 10.18632/ONCOTARGET.27886.

[141] S. Kim *et al.*, "Abstract LBA009: Orally available ENPP1 inhibitor, TXN10128, restores STING activation in tumor microenvironment and confers anti-tumor responses in combination with immune checkpoint blockade," *Mol. Cancer Ther.*, vol. 20, no. 12_Supplement, pp. LBA009–LBA009, Dec. 2021, doi: 10.1158/1535-7163.TARG-21-LBA009.

[142] I. Csiki *et al.*, "First-in-human experience using RBS2418, an oral ENPP1 inhibitor within an expanded access protocol in combination with pembrolizumab in a patient with metastatic adrenal cancer.," *https://doi.org/10.1200/JCO.2022.40.16_suppl.e14550*, vol. 40, no. 16_suppl, pp. e14550–e14550, Jun. 2022, doi: 10.1200/JCO.2022.40.16_SUPPL.E14550.

[143] H. Ishikawa and G. N. Barber, "STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling," *Nature*, vol. 455, no. 7213, pp. 674–678, Oct. 2008, doi: 10.1038/NATURE07317.

[144] T. Xia, H. Konno, J. Ahn, and G. N. Barber, "Deregulation of STING Signaling in Colorectal Carcinoma Constrains DNA Damage Responses and Correlates With Tumorigenesis," *Cell Rep.*, vol. 14, no. 2, pp. 282–297, Jan. 2016, doi: 10.1016/J.CELREP.2015.12.029.

[145] H. Vasiyani *et al.*, "The analog of cGAMP, c-di-AMP, activates STING mediated cell death pathway in estrogen-receptor negative breast cancer cells," *Apoptosis*, vol. 26, no. 5–6, pp. 293–306, Jun. 2021, doi: 10.1007/S10495-021-01669-X.

[146] S. Kitajima *et al.*, "Suppression of STING associated with LKB1 loss in KRAS-

driven lung cancer," *Cancer Discov.*, vol. 9, no. 1, p. 34, Jan. 2019, doi: 10.1158/2159-8290.CD-18-0689.

[147] Y. S. Tan *et al.*, "Mitigating SOX2-potentiated Immune Escape of Head and Neck Squamous Cell Carcinoma with a STING-inducing Nanosatellite Vaccine," *Clin. Cancer Res.*, vol. 24, no. 17, pp. 4242–4255, Sep. 2018, doi: 10.1158/1078-0432.CCR-17-2807.

[148] A. Li, M. Yi, S. Qin, Y. Song, Q. Chu, and K. Wu, "Activating cGAS-STING pathway for the optimal effect of cancer immunotherapy," *J. Hematol. Oncol. 2019 121*, vol. 12, no. 1, pp. 1–12, Apr. 2019, doi: 10.1186/S13045-019-0721-X.

[149] Y. Liu *et al.*, "RIG-I-Mediated STING Upregulation Restricts Herpes Simplex Virus 1 Infection," *J. Virol.*, vol. 90, no. 20, p. 9406, Oct. 2016, doi: 10.1128/JVI.00748-16.

[150] P. G. Ekert and D. L. Vaux, "Apoptosis and the immune system," *Br. Med. Bull.*, vol. 53, no. 3, pp. 591–603, 1997, doi: 10.1093/OXFORDJOURNALS.BMB.A011632.

[151] M. F. Gulen *et al.*, "Signalling strength determines proapoptotic functions of STING," *Nat. Commun. 2017 81*, vol. 8, no. 1, pp. 1–10, Sep. 2017, doi: 10.1038/s41467-017-00573-w.

[152] D. Chandra *et al.*, "STING ligand c-di-GMP improves cancer vaccination against metastatic breast cancer," *Cancer Immunol. Res.*, vol. 2, no. 9, p. 901, Sep. 2014, doi: 10.1158/2326-6066.CIR-13-0123.

[153] C. H. A. Tang *et al.*, "Agonist-mediated activation of STING induces apoptosis in malignant B cells," *Cancer Res.*, 2016, doi: 10.1158/0008-5472.CAN-15-1885.

[154] C. Zierhut and H. Funabiki, "Regulation and Consequences of cGAS Activation by Self-DNA," *Trends Cell Biol.*, vol. 30, no. 8, p. 594, Aug. 2020, doi: 10.1016/J.TCB.2020.05.006.

[155] C. Groth *et al.*, "Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression," *Br. J. Cancer*, vol. 120, no. 1, pp. 16–25, Jan. 2019, doi: 10.1038/S41416-018-0333-1.

[156] J. Markowitz, R. Wesolowski, T. Papenfuss, T. R. Brooks, and W. E. Carson, "Myeloid Derived Suppressor Cells in Breast Cancer," *Breast Cancer Res. Treat.*, vol. 140, no. 1, p. 13, Jul. 2013, doi: 10.1007/S10549-013-2618-7.

[157] Y. Wang, Y. Ding, N. Guo, and S. Wang, "MDSCs: Key criminals of tumor pre-metastatic niche formation," *Front. Immunol.*, vol. 10, no. FEB, p. 172, 2019, doi: 10.3389/FIMMU.2019.00172/BIBTEX.

[158] R. Yu, B. Zhu, and D. Chen, "Type I interferon-mediated tumor immunity and its role in immunotherapy," *Cell. Mol. Life Sci.*, vol. 79, no. 3, p. 191, Mar. 2022, doi: 10.1007/S00018-022-04219-Z.

[159] P. Fitzgerald-Bocarsly and D. Feng, "The role of type I interferon production by dendritic cells in host defense," *Biochimie*, vol. 89, no. 6–7, pp. 843–855, Jun. 2007, doi: 10.1016/J.BIOCHI.2007.04.018.

[160] A. Amouzegar, M. Chelvanambi, J. N. Filderman, W. J. Storkus, and J. J. Luke, "STING Agonists as Cancer Therapeutics," *Cancers (Basel).*, vol. 13, no. 11, Jun. 2021, doi: 10.3390/CANCERS13112695.

[161] R. E. Vatner and E. M. Janssen, "STING, DCs and the link between innate and adaptive tumor immunity," *Mol. Immunol.*, vol. 110, p. 13, Jun. 2019, doi: 10.1016/J.MOLIMM.2017.12.001.

[162] A. Amouzegar, M. Chelvanambi, J. N. Filderman, W. J. Storkus, and J. J. Luke, "STING Agonists as Cancer Therapeutics," *Cancers (Basel).*, vol. 13, no. 11, Jun. 2021, doi: 10.3390/CANCERS13112695.

[163] X. Che, J. Zhang, H. Quan, L. Yang, and Y. Q. Gao, "CDNs-STING Interaction Mechanism Investigations and Instructions on Design of CDN-Derivatives," *J. Phys. Chem. B*, vol. 122, no. 6, pp. 1862–1868, Feb. 2018, doi: 10.1021/ACS.JPCB.7B12276.

[164] C. M. Downey, M. Aghaei, R. A. Schwendener, and F. R. Jirik, "DMXAA Causes Tumor Site-Specific Vascular Disruption in Murine Non-Small Cell Lung Cancer, and like the Endogenous Non-Canonical Cyclic Dinucleotide STING Agonist, 2′3′-cGAMP, Induces M2 Macrophage Repolarization," *PLoS One*, vol. 9, no. 6, p.

e99988, Jun. 2014, doi: 10.1371/JOURNAL.PONE.0099988.

[165] J. M. Weiss *et al.*, "The STING agonist DMXAA triggers a cooperation between T lymphocytes and myeloid cells that leads to tumor regression," *Oncoimmunology*, vol. 6, no. 10, Oct. 2017, doi: 10.1080/2162402X.2017.1346765.

[166] A. H. Zaidi *et al.*, "Intratumoral immunotherapy with STING agonist, ADU-S100, induces CD8+ T-cell mediated anti-tumor immunity in an esophageal adenocarcinoma model," *Oncotarget*, vol. 12, no. 4, pp. 292–303, Feb. 2021, doi: 10.18632/ONCOTARGET.27886.

[167] W. Chang *et al.*, "Discovery of MK-1454: A Potent Cyclic Dinucleotide Stimulator of Interferon Genes Agonist for the Treatment of Cancer," *J. Med. Chem.*, vol. 65, no. 7, pp. 5675–5689, Apr. 2022, doi: 10.1021/ACS.JMEDCHEM.1C02197.

[168] S. V. Challa *et al.*, "Preclinical studies of SB 11285, a novel STING agonist for immuno-oncology.," *https://doi.org/10.1200/JCO.2017.35.15_suppl.e14616*, vol. 35, no. 15_suppl, pp. e14616–e14616, May 2017, doi: 10.1200/JCO.2017.35.15_SUPPL.E14616.

[169] M. Smith *et al.*, "Abstract 5567: In vivo administration of the STING agonist, JNJ-67544412, leads to complete regression of established murine subcutaneous tumors," *Cancer Res.*, vol. 80, no. 16_Supplement, pp. 5567–5567, Aug. 2020, doi: 10.1158/1538-7445.AM2020-5567.

[170] C. Ding, Z. Song, A. Shen, T. Chen, and A. Zhang, "Small molecules targeting the innate immune cGAS–STING–TBK1 signaling pathway," *Acta Pharm. Sin. B*, vol. 10, no. 12, pp. 2272–2298, Dec. 2020, doi: 10.1016/J.APSB.2020.03.001.

[171] A. Ghaffari *et al.*, "STING agonist therapy in combination with PD-1 immune checkpoint blockade enhances response to carboplatin chemotherapy in high-grade serous ovarian cancer," *Br. J. Cancer 2018 1194*, vol. 119, no. 4, pp. 440–449, Jul. 2018, doi: 10.1038/s41416-018-0188-5.

[172] T. Nakamura *et al.*, "STING agonist loaded lipid nanoparticles overcome anti-PD-1 resistance in melanoma lung metastasis via NK cell activation," *J. Immunother. Cancer*, vol. 9, no. 7, Jul. 2021, doi: 10.1136/JITC-2021-002852.

[173] M. Yi *et al.*, "Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors," *J. Hematol. Oncol.*, vol. 15, no. 1, p. 142, Dec. 2022, doi: 10.1186/S13045-022-01363-8.

[174] K. Li *et al.*, "The lipid platform increases the activity of STING agonists to synergize checkpoint blockade therapy against melanoma," *Biomater. Sci.*, vol. 9, no. 3, pp. 765–773, Feb. 2021, doi: 10.1039/D0BM00870B.

[175] M. Yin *et al.*, "STING agonist enhances the efficacy of programmed death-ligand 1 monoclonal antibody in breast cancer immunotherapy by activating the interferon-β signalling pathway," *Cell Cycle*, vol. 21, no. 8, pp. 767–779, 2022, doi: 10.1080/15384101.2022.2029996.

[176] N. Cheng *et al.*, "A nanoparticle-incorporated STING activator enhances antitumor immunity in PD-L1-insensitive models of triple-negative breast cancer.," *undefined*, vol. 3, no. 22, Nov. 2018, doi: 10.1172/JCI.INSIGHT.120638.

[177] A. Sallets, S. Robinson, A. Kardosh, and R. Levy, "Enhancing immunotherapy of STING agonist for lymphoma in preclinical models," *Blood Adv.*, vol. 2, no. 17, pp. 2230–2241, Sep. 2018, doi: 10.1182/BLOODADVANCES.2018020040.

[178] J. Le Naour, L. Zitvogel, L. Galluzzi, E. Vacchelli, and G. Kroemer, "Trial watch: STING agonists in cancer therapy," *Oncoimmunology*, vol. 9, no. 1, Jan. 2020, doi: 10.1080/2162402X.2020.1777624.

[179] M. Lv *et al.*, "Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy," *Cell Res.*, vol. 30, no. 11, p. 966, Nov. 2020, doi: 10.1038/S41422-020-00395-4.

[180] C. Wang *et al.*, "Maintaining manganese in tumor to activate cGAS-STING pathway evokes a robust abscopal anti-tumor effect," *J. Control. Release*, vol. 331, pp. 480–490, Mar. 2021, doi: 10.1016/J.JCONREL.2021.01.036.

[181] K. I. Onyedibe, M. Wang, and H. O. Sintim, "ENPP1, an Old Enzyme with New Functions, and Small Molecule Inhibitors—A STING in the Tale of ENPP1," *Molecules*, vol. 24, no. 22, Nov. 2019, doi: 10.3390/MOLECULES24224192.

[182] S. Sharma, A. Weston, T. Thode, E. Gomez, M. Kaadige, and H. Vankayalapti, "Abstract 1932: Discovery of ENPP1 inhibitors as agonists of STING pathway," *Cancer Res.*, vol. 78, no. 13_Supplement, pp. 1932–1932, Jul. 2018, doi: 10.1158/1538-7445.AM2018-1932.

[183] J. Baird *et al.*, "MV-626, a potent and selective inhibitor of ENPP1 enhances STING activation and augments T-cell mediated anti-tumor activity in vivo," *Soc. Immunother. Cancer 2018 Annu. Meet. Posters*, Nov. 2018, Accessed: Nov. 06, 2022. [Online]. Available: https://digitalcommons.psjhealth.org/sitc2018/7.

[184] C. Hong *et al.*, "cGAS-STING drives the IL-6-dependent survival of chromosomally instable cancers," *Nature*, vol. 607, no. 7918, pp. 366–373, Jul. 2022, doi: 10.1038/S41586-022-04847-2.

[185] J. Pei *et al.*, "STAT3 inhibition enhances CDN-induced STING signaling and antitumor immunity," *Cancer Lett.*, vol. 450, pp. 110–122, May 2019, doi: 10.1016/J.CANLET.2019.02.029.

[186] M. A. Suter *et al.*, "cGAS–STING cytosolic DNA sensing pathway is suppressed by JAK2-STAT3 in tumor cells," *Sci. Reports 2021 111*, vol. 11, no. 1, pp. 1–13, Mar. 2021, doi: 10.1038/s41598-021-86644-x.

[187] M. A. Suter *et al.*, "cGAS–STING cytosolic DNA sensing pathway is suppressed by JAK2-STAT3 in tumor cells," *Sci. Reports 2021 111*, vol. 11, no. 1, pp. 1–13, Mar. 2021, doi: 10.1038/s41598-021-86644-x.

[188] S. S. Al-Asmari, A. Rajapakse, T. R. Ullah, G. Pépin, L. V. Croft, and M. P. Gantier, "Pharmacological Targeting of STING-Dependent IL-6 Production in Cancer Cells," *Front. cell Dev. Biol.*, vol. 9, Jan. 2022, doi: 10.3389/FCELL.2021.709618.

[189] E. R. Williams, "HER2 reduces the STING," *Sci. Signal.*, vol. 12, no. 593, Aug. 2019, doi: 10.1126/SCISIGNAL.AAY9834.

[190] S. Wu *et al.*, "HER2 recruits AKT1 to disrupt STING signalling and suppress antiviral defence and antitumour immunity," *Nat. Cell Biol.*, vol. 21, no. 8, pp. 1027–1040, Aug. 2019, doi: 10.1038/S41556-019-0352-Z.

[191] G. J. Seo *et al.*, "Akt Kinase-Mediated Checkpoint of cGAS DNA Sensing Pathway," *Cell Rep.*, vol. 13, no. 2, pp. 440–449, Oct. 2015, doi: 10.1016/J.CELREP.2015.09.007.

[192] Q. Wang *et al.*, "STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer," *Nat. Commun.*, vol. 13, no. 1, Dec. 2022, doi: 10.1038/S41467-022-30568-1.

[193] C. Pantelidou *et al.*, "STING agonism enhances anti-tumor immune responses and therapeutic efficacy of PARP inhibition in BRCA-associated breast cancer," *npj Breast Cancer 2022 81*, vol. 8, no. 1, pp. 1–6, Sep. 2022, doi: 10.1038/s41523-022-00471-5.

[194] B. D. Zhang *et al.*, "STING and TLR7/8 agonists-based nanovaccines for synergistic antitumor immune activation," *Nano Res. 2022 157*, vol. 15, no. 7, pp. 6328–6339, Apr. 2022, doi: 10.1007/S12274-022-4282-X.

[195] N. K. Wolf *et al.*, "Synergy of a STING agonist and an IL-2 superkine in cancer immunotherapy against MHC I-deficient and MHC I+ tumors," *Proc. Natl. Acad. Sci. U. S. A.*, vol. 119, no. 22, p. e2200568119, May 2022, doi: 10.1073/PNAS.2200568119/SUPPL_FILE/PNAS.2200568119.SAPP.PDF.

[196] J. Shi *et al.*, "STING agonist and IDO inhibitor combination therapy inhibits tumor progression in murine models of colorectal cancer," *Cell. Immunol.*, vol. 366, p. 104384, Aug. 2021, doi: 10.1016/J.CELLIMM.2021.104384.

[197] O. Sokolowska *et al.*, "Immune checkpoint inhibition improves antimyeloma activity of bortezomib and STING agonist combination in Vk*MYC preclinical model," *Clin. Exp. Med.*, 2022, doi: 10.1007/S10238-022-00878-1.

[198] L. Zhu *et al.*, "Combination of STING agonist and CXCR3 antagonist disrupts immune tolerance to overcome anti-PD-L1 resistance in lung adenocarcinoma under oxidative stress," *Gene*, vol. 851, p. 146962, Jan. 2023, doi: 10.1016/J.GENE.2022.146962.

[199] S. Sharma, A. Weston, T. Thode, E. Gomez, M. Kaadige, and H. Vankayalapti,

"Abstract 1932: Discovery of ENPP1 inhibitors as agonists of STING pathway," *Cancer Res.*, vol. 78, no. 13_Supplement, pp. 1932–1932, Jul. 2018, doi: 10.1158/1538-7445.AM2018-1932.

[200] J. Pei *et al.*, "STAT3 inhibition enhances CDN-induced STING signaling and antitumor immunity," *Cancer Lett.*, vol. 450, pp. 110–122, May 2019, doi: 10.1016/J.CANLET.2019.02.029.

[201] C. C. Ou *et al.*, "Downregulation of HER2 by RIG1 involves the PI3K/Akt pathway in ovarian cancer cells," *Carcinogenesis*, 2008, doi: 10.1093/carcin/bgm263.

[202] S. Wu *et al.*, "HER2 recruits AKT1 to disrupt STING signalling and suppress antiviral defence and antitumour immunity," *Nat. Cell Biol. 2019 218*, vol. 21, no. 8, pp. 1027–1040, Jul. 2019, doi: 10.1038/s41556-019-0352-z.

[203] E. R. Williams, "HER2 reduces the STING," *Sci. Signal.*, vol. 12, no. 593, Aug. 2019, doi: 10.1126/SCISIGNAL.AAY9834.

[204] "HER2 Blocks the cGAS-STING-Mediated Immune Response to DNA Damage," *Cancer Discov.*, vol. 9, no. 9, p. OF12, Sep. 2019, doi: 10.1158/2159-8290.CD-RW2019-117/338036/P/HER2-BLOCKS-THE-CGAS-STING-MEDIATED-IMMUNE.

[205] S. hwan Jeong, M. J. Yang, S. Choi, J. M. Kim, and G. Y. Koh, "Refractoriness of STING therapy is relieved by AKT inhibitor through effective vascular disruption in tumour," *Nat. Commun. 2021 121*, vol. 12, no. 1, pp. 1–18, Jul. 2021, doi: 10.1038/s41467-021-24603-w.

[206] Q. Wang *et al.*, "STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer," *Nat. Commun. 2022 131*, vol. 13, no. 1, pp. 1–17, May 2022, doi: 10.1038/s41467-022-30568-1.

[207] S. S. Al-Asmari, A. Rajapakse, T. R. Ullah, G. Pépin, L. V. Croft, and M. P. Gantier, "Pharmacological Targeting of STING-Dependent IL-6 Production in Cancer Cells," *Front. Cell Dev. Biol.*, vol. 9, p. 3835, Jan. 2022, doi: 10.3389/FCELL.2021.709618/BIBTEX.

[208] L. Wang *et al.*, "Inhibition of the ATM/Chk2 axis promotes cGAS/STING signaling in ARID1A-deficient tumors," *J. Clin. Invest.*, vol. 130, no. 11, pp. 5951–5966, Nov. 2020, doi: 10.1172/JCI130445.

[209] Q. Zhang *et al.*, "Inhibition of ATM increases interferon signaling and sensitizes pancreatic cancer to immune checkpoint blockade therapy," *Cancer Res.*, vol. 79, no. 15, pp. 3940–3951, Aug. 2019, doi: 10.1158/0008-5472.CAN-19-0761.

[210] M. Hu *et al.*, "ATM inhibition enhances cancer immunotherapy by promoting mtDNA leakage and cGAS/STING activation," *J. Clin. Invest.*, vol. 131, no. 3, Feb. 2021, doi: 10.1172/JCI139333.

[211] G. J. Seo *et al.*, "Akt Kinase-Mediated Checkpoint of cGAS DNA Sensing Pathway," *Cell Rep.*, vol. 13, no. 2, pp. 440–449, Oct. 2015, doi: 10.1016/J.CELREP.2015.09.007.

[212] A. M. Esteves, E. Papaevangelou, P. Dasgupta, and C. Galustian, "Combination of Interleukin-15 With a STING Agonist, ADU-S100 Analog: A Potential Immunotherapy for Prostate Cancer.," *Front. Oncol.*, vol. 11, p. 621550, Mar. 2021, doi: 10.3389/fonc.2021.621550.

[213] R. FA, H. PD, W. J, A. V, S. DA, and Z. F, "Genome engineering using the CRISPR-Cas9 system," *Nat. Protoc.*, vol. 8, no. 11, pp. 2281–2308, 2013, doi: 10.1038/NPROT.2013.143.

[214] D. Tomar, L. Sripada, P. Prajapati, R. Singh, A. K. Singh, and R. Singh, "Nucleo-Cytoplasmic Trafficking of TRIM8, a Novel Oncogene, Is Involved in Positive Regulation of TNF Induced NF-κB Pathway," *PLoS One*, vol. 7, no. 11, Nov. 2012, doi: 10.1371/JOURNAL.PONE.0048662.

[215] D. Tomar, R. Singh, A. K. Singh, C. D. Pandya, and R. Singh, "TRIM13 regulates ER stress induced autophagy and clonogenic ability of the cells," *Biochim. Biophys. Acta - Mol. Cell Res.*, vol. 1823, no. 2, pp. 316–326, 2012, doi: 10.1016/j.bbamcr.2011.11.015.

[216] M. G. Nagy A, "Kaplan-Meier plotter [Breast]," *Nagy A, Munkárcsy G, Győrffy B. Pancancer survival analysis of cancer hallmark genes, Scientific Reports, 2021 Mar*

15;11(1):6047., doi: 10.1038/s41598-021-84787-5, 1BC. https://kmplot.com/analysis/ (accessed Jul. 18, 2021).

[217] T. Li *et al.*, "TIMER2.0 for analysis of tumor-infiltrating immune cells," *Nucleic Acids Res.*, vol. 48, no. W1, pp. W509–W514, Jul. 2021, doi: 10.1093/NAR/GKAA407.

[218] K. Bhatelia *et al.*, "Antiviral signaling protein MITA acts as a tumor suppressor in breast cancer by regulating NF-κB induced cell death," *Biochim. Biophys. Acta - Mol. Basis Dis.*, 2014, doi: 10.1016/j.bbadis.2013.11.006.

[219] R. D. A. Wilkinson *et al.*, "Topoisomerase II inhibitors induce cGAS-STING dependent inflammation resulting in cytokine induction and immune checkpoint activation," *bioRxiv*, p. 764662, Oct. 2019, doi: 10.1101/764662.

[220] A. Nagelkerke and P. N. Span, "Staining Against Phospho-H2AX (γ-H2AX) as a Marker for DNA Damage and Genomic Instability in Cancer Tissues and Cells," *Adv. Exp. Med. Biol.*, vol. 899, pp. 1–10, 2016, doi: 10.1007/978-3-319-26666-4_1.

[221] W. Wang, A. M. Mani, and Z.-H. Wu, "DNA damage-induced nuclear factor-kappa B activation and its roles in cancer progression," *J. cancer metastasis Treat.*, vol. 3, no. 3, p. 45, Mar. 2017, doi: 10.20517/2394-4722.2017.03.

[222] W. Wang, A. M. Mani, and Z.-H. Wu, "DNA damage-induced nuclear factor-kappa B activation and its roles in cancer progression," *J. cancer metastasis Treat.*, vol. 3, no. 3, p. 45, Mar. 2017, doi: 10.20517/2394-4722.2017.03.

[223] B. C. McFarland *et al.*, "NF-κB-Induced IL-6 Ensures STAT3 Activation and Tumor Aggressiveness in Glioblastoma," *PLoS One*, vol. 8, no. 11, p. e78728, Nov. 2013, doi: 10.1371/JOURNAL.PONE.0078728.

[224] L. Xia *et al.*, "Role of the NFκB-signaling pathway in cancer," *Onco. Targets. Ther.*, vol. 11, p. 2063, Apr. 2018, doi: 10.2147/OTT.S161109.

[225] J. Mauer, J. L. Denson, and J. C. Brüning, "Versatile functions for IL-6 in metabolism and cancer," *Trends Immunol.*, vol. 36, no. 2, pp. 92–101, Feb. 2015, doi: 10.1016/J.IT.2014.12.008.

[226] H. Sato *et al.*, "DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells," *Nat. Commun. 2017 81*, vol. 8, no. 1, pp. 1–11, Nov. 2017, doi: 10.1038/s41467-017-01883-9.

[227] Z. Li *et al.*, "A novel STAT3 inhibitor, HJC0152, exerts potent antitumor activity in glioblastoma," *Am. J. Cancer Res.*, vol. 9, no. 4, p. 699, 2019, Accessed: Jul. 18, 2021. [Online]. Available: /pmc/articles/PMC6511646/.

[228] M. W. G. D. Y. Z. R. P. C. A. J. D. JF Bromberg, "Stat3 as an oncogene," *Cell*, vol. 98, no. 3, pp. 295–303, Aug. 1999, doi: 10.1016/s0092-8674(00)81959-5.

[229] G. MB, R. R, M. R, O. D, G. E, and M. E, "Inhibition of Stat3 increases doxorubicin sensitivity in a human metastatic breast cancer cell line," *Cancer Lett.*, vol. 258, no. 2, pp. 181–188, Dec. 2007, doi: 10.1016/J.CANLET.2007.08.019.

[230] T. Li *et al.*, "TIMER: A web server for comprehensive analysis of tumor-infiltrating immune cells," *Cancer Res.*, vol. 77, no. 21, pp. e108–e110, Nov. 2017, doi: 10.1158/0008-5472.CAN-17-0307/SUPPLEMENTARY-VIDEO-S1.

[231] Y. Bareche *et al.*, "Unraveling Triple-Negative Breast Cancer Tumor Microenvironment Heterogeneity: Towards an Optimized Treatment Approach," *JNCI J. Natl. Cancer Inst.*, vol. 112, no. 7, pp. 708–719, Jul. 2020, doi: 10.1093/JNCI/DJZ208.

[232] B. Y. da Hoong, Y. H. Gan, H. Liu, and E. S. Chen, "cGAS-STING pathway in oncogenesis and cancer therapeutics," *Oncotarget*, vol. 11, no. 30, pp. 2930–2955, 2020, doi: 10.18632/oncotarget.27673.

[233] H. A. Wahba and H. A. El-Hadaad, "Current approaches in treatment of triple-negative breast cancer," *Cancer Biol. Med.*, vol. 12, no. 2, p. 106, Jun. 2015, doi: 10.7497/J.ISSN.2095-3941.2015.0030.

[234] D. E. Johnson, R. A. O'Keefe, and J. R. Grandis, "Targeting the IL-6/JAK/STAT3 signalling axis in cancer," *Nat. Rev. Clin. Oncol.*, vol. 15, no. 4, p. 234, Apr. 2018, doi: 10.1038/NRCLINONC.2018.8.

[235] P. EE *et al.*, "Activation of STING-Dependent Innate Immune Signaling By S-Phase-Specific DNA Damage in Breast Cancer," *J. Natl. Cancer Inst.*, vol. 109, no.

1, Jan. 2016, doi: 10.1093/JNCI/DJW199.

[236] L. L. Bu *et al.*, "STAT3 Induces Immunosuppression by Upregulating PD-1/PD-L1 inHNSCC," *J. Dent. Res.*, vol. 96, no. 9, p. 1027, Aug. 2017, doi: 10.1177/0022034517712435.

[237] I. Zerdes *et al.*, "STAT3 Activity Promotes Programmed-Death Ligand 1 Expression and Suppresses Immune Responses in Breast Cancer," *Cancers (Basel).*, vol. 11, no. 10, Oct. 2019, doi: 10.3390/CANCERS11101479.

[238] K. V. M. Huber *et al.*, "Proteome-wide drug and metabolite interaction mapping by thermal-stability profiling," *Nat. Methods*, vol. 12, no. 11, pp. 1055–1057, Nov. 2015, doi: 10.1038/NMETH.3590.

[239] R. Raja and G. C. Sen, "The antiviral action of the RIG-I induced pathway of apoptosis (RIPA) is enhanced by its ability to degrade Otulin, which deubiquitinates IRF3," *Cell Death Differ. 2021 293*, vol. 29, no. 3, pp. 504–513, Sep. 2021, doi: 10.1038/s41418-021-00870-4.

[240] F. Sun, Z. Liu, Z. Yang, S. Liu, and W. Guan, "The emerging role of STING-dependent signaling on cell death," *Immunol. Res.*, vol. 67, no. 2–3, pp. 290–296, Jun. 2019, doi: 10.1007/S12026-019-09073-Z.

[241] N. Vargas-Rondón, V. E. Villegas, and M. Rondón-Lagos, "The Role of Chromosomal Instability in Cancer and Therapeutic Responses," *Cancers (Basel).*, vol. 10, no. 1, Jan. 2017, doi: 10.3390/CANCERS10010004.

[242] A. Basit, M. G. Cho, E. Y. Kim, D. Kwon, S. J. Kang, and J. H. Lee, "The cGAS/STING/TBK1/IRF3 innate immunity pathway maintains chromosomal stability through regulation of p21 levels," *Exp. Mol. Med.*, vol. 52, no. 4, pp. 643–657, Apr. 2020, doi: 10.1038/S12276-020-0416-Y.

[243] "Cancer Cell–Astrocyte Gap Junctions Promote Brain Metastasis Formation," *Cancer Discov.*, vol. 6, no. 7, pp. OF10–OF10, Jul. 2016, doi: 10.1158/2159-8290.CD-RW2016-096.

[244] S. Sormendi and B. Wielockx, "Hypoxia Pathway Proteins As Central Mediators of Metabolism in the Tumor Cells and Their Microenvironment," *Front. Immunol.*,

vol. 9, no. JAN, p. 1, Jan. 2018, doi: 10.3389/FIMMU.2018.00040.

[245] M. Zhang, A. V. Lee, and J. M. Rosen, "The Cellular Origin and Evolution of Breast Cancer," *Cold Spring Harb. Perspect. Med.*, vol. 7, no. 3, Mar. 2017, doi: 10.1101/CSHPERSPECT.A027128.

[246] S. Chattopadhyay *et al.*, "Viral apoptosis is induced by IRF-3-mediated activation of Bax," *EMBO J.*, vol. 29, no. 10, pp. 1762–1773, May 2010, doi: 10.1038/EMBOJ.2010.50.

[247] H. Yanai *et al.*, "Revisiting the role of IRF3 in inflammation and immunity by conditional and specifically targeted gene ablation in mice," *Proc. Natl. Acad. Sci. U. S. A.*, vol. 115, no. 20, pp. 5253–5258, May 2018, doi: 10.1073/PNAS.1803936115.

[248] J. K. Won and S. F. Bakhoum, "The cytosolic DNA-sensing cGAS-STING pathway in cancer," *Cancer Discov.*, vol. 10, no. 1, p. 26, Jan. 2020, doi: 10.1158/2159-8290.CD-19-0761.

[249] M. Moustakas, "The role of metal ions in biology, biochemistry and medicine," *Materials (Basel).*, vol. 14, no. 3, pp. 1–4, Feb. 2021, doi: 10.3390/MA14030549.

[250] C. Wang, R. Zhang, X. Wei, M. Lv, and Z. Jiang, "Metalloimmunology: The metal ion-controlled immunity," *Adv. Immunol.*, vol. 145, pp. 187–241, Jan. 2020, doi: 10.1016/BS.AI.2019.11.007.

[251] C. Wang *et al.*, "Manganese Increases the Sensitivity of the cGAS-STING Pathway for Double-Stranded DNA and Is Required for the Host Defense against DNA Viruses," *Immunity*, vol. 48, no. 4, pp. 675-687.e7, Apr. 2018, doi: 10.1016/J.IMMUNI.2018.03.017.

[252] Z. Zhao, Z. Ma, B. Wang, Y. Guan, X. D. Su, and Z. Jiang, "Mn2+ Directly Activates cGAS and Structural Analysis Suggests Mn2+ Induces a Noncanonical Catalytic Synthesis of 2'3'-cGAMP," *Cell Rep.*, vol. 32, no. 7, Aug. 2020, doi: 10.1016/J.CELREP.2020.108053.

[253] T. M. Abu Samaan, M. Samec, A. Liskova, P. Kubatka, and D. Büsselberg, "Paclitaxel's Mechanistic and Clinical Effects on Breast Cancer," *Biomolecules*,

vol. 9, no. 12, Nov. 2019, doi: 10.3390/BIOM9120789.

[254] S. Lohard *et al.*, "STING-dependent paracriny shapes apoptotic priming of breast tumors in response to anti-mitotic treatment," *Nat. Commun.*, vol. 11, no. 1, Dec. 2020, doi: 10.1038/S41467-019-13689-Y.

[255] Y. Hu *et al.*, "Paclitaxel induces micronucleation and activates pro-inflammatory cGAS-STING signaling in triple-negative breast cancer," *Mol. Cancer Ther.*, vol. 20, no. 12, pp. 2553–2567, Dec. 2021, doi: 10.1158/1535-7163.MCT-21-0195/673439/AM/PACLITAXEL-INDUCES-MICRONUCLEATION-AND-ACTIVATES.

[256] C. Zierhut, N. Yamaguchi, M. Paredes, J. D. Luo, T. Carroll, and H. Funabiki, "The Cytoplasmic DNA Sensor cGAS Promotes Mitotic Cell Death," *Cell*, vol. 178, no. 2, pp. 302-315.e23, Jul. 2019, doi: 10.1016/J.CELL.2019.05.035.